153
Participants
Start Date
September 16, 2019
Primary Completion Date
May 19, 2020
Study Completion Date
November 17, 2020
bermekimab
bermekimab 2 mL (200 mg/mL) pre-filled syringe
placebo
placebo 2 mL pre-filled syringe
Icahn School of Medicine at Mount Sinai, New York
Dominion Medical Associates, Inc., Richmond
Advanced Medical Research, Sandy Springs
Meridian Clinical Research, LLC, Savannah
Columbus Regional Research Institute, Columbus
Accel Clinical Research, Orlando
Physica Clinical Research, Sebastian
Florida Academic Dermatology Centers, Coral Gables
Floridian Research Institute, Miami
Florida International Medical Research, Miami
Doral Medical Research, Doral
P&S Research, LLC, Miami
Visionary Investigators Network, Aventura
Integrated Clincal Research LLC, West Palm Beach
Avita Clinical Research, Tampa
Forcare Clinical Research, Inc., Tampa
Clinical Research Solutions, LLC, Milan
ClinOhio Research Services, Columbus
University Hospitals Cleveland Medical Center, Cleveland
Dawes Fretzin Clinical Research Group, Indianapolis
Randall Dermatology & Cosmetic Surgery, West Lafayette
Revival Research Institute, LLC, Troy
Oakland Hills Dermatology, Auburn Hills
Washington University in St. Louis, St Louis
Clinical Trials of SWLA, Lake Charles
Meridian Clinical Research, LLC, Baton Rouge
Progressive Clinical Research, San Antonio
Desert Sky, Gilbert
University of Southern California, Los Angeles
Dermatology Research Associates, Los Angeles
Marvel Clinical Research, Huntington Beach
Syrentis Clinical Research, Santa Ana
Wolverine Clinical Trials, Santa Ana
Janssen Research & Development, LLC
INDUSTRY